What GT Metabolic Solutions does

GT Metabolic Solutions, Inc. is a privately-held medical device company developing the MagDI™ System, a proprietary magnetic compression anastomosis platform for bariatric, metabolic, and digestive surgery. The core technology is Delayed Anastomosis Technology (DAT), which uses paired magnets — Parylene-C coated neodymium magnets in titanium shells with PGLA bio-fragmentable flanges — to create side-to-side duodeno-ileal anastomosis without cutting, suturing, stapling, or permanent implants. The patient swallows the first magnet which travels to the duodenum, while the second is positioned laparoscopically in the ileum; the magnets compress tissue and fuse over 7–21 days, after which the magnets naturally expel, leaving no foreign material. The product platform comprises MagDI™ Magnets (40mm and 50mm variants), a disposable Delivery System, a reusable Laparoscopic Positioning Device offered in five magnetic strengths, and a Magnetic Retrieval Device for intra-procedure removal.

The company monetizes through sale of these sterile, disposable (and partially reusable) medical devices to bariatric and metabolic surgeons at hospitals and Ambulatory Surgery Centers, distributed via a direct enterprise field sales motion that includes formal surgeon training enrollment and proctoring. The FDA granted De Novo marketing authorization for the first-generation MagDI™ System in July 2024 (DEN240013), followed by 510(k) clearances for the 40mm (October 2024) and 50mm (February 2025) magnets. Customers served include high-volume bariatric centers such as Ventura Advanced Surgical Associates, where the first US cases were completed in November 2024 by Dr. Helmuth Billy. The company operates internationally with country-specific IFU documentation across the Americas, Europe, the Middle East, and Oceania.

Founded in 2020 by Thierry Thaure (CEO) and Dr. Michel Gagner (CMO), GT Metabolic is headquartered in Saint Michael/Minneapolis, MN and operates with 11–50 employees. The co-founder team combines Dr. Gagner's clinical authority as a pioneer of laparoscopic duodenal switch and sleeve gastrectomy (with the underlying IP dating to 2007 across 18 patents) and Mr. Thaure's medtech operating track record, including co-founding Cephea Valve Technologies (acquired by Abbott for $200M) and serving as founding VP Sales & Marketing at Intuitive Surgical. The company has raised approximately $32.6M+ across three disclosed financing rounds led or arranged by Ceros Capital Markets, HealthTech Capital, and Ironwood Ventures.

Name

GT Metabolic Solutions

Legal name

GT Metabolic Solutions, Inc.

Website

https://gtmetabolic.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

GT Metabolic Solutions develops the MagDI™ System, an incisionless magnetic compression anastomosis platform that creates side-to-side duodeno-ileal connections for bariatric and metabolic surgeons at hospitals and ambulatory surgery centers.

Ownership category

akta.pro rank

Product category

Bariatric & Metabolic Surgical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

Keywords

• Magnetic anastomosis devices
• Bariatric surgical devices
• Minimally invasive surgery
• Duodeno-ileal anastomosis systems
• Metabolic surgery technology

Headquarters

HQ city

Saint Michael

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. MagDI™ System Medical Devices: GT Metabolic generates revenue through sale of its magnetic compression anastomosis devices including magnets (40mm and 50mm), delivery systems, laparoscopic positioning devices (LPD), and magnetic retrieval devices (MRD). Devices are sterile and disposable (except LPD which is reusable). Sold to bariatric/metabolic surgeons at hospitals and ambulatory surgery centers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

GT Metabolic Solutions develops and commercializes the MagDI™ System, a proprietary magnetic compression anastomosis device platform for bariatric, metabolic, and digestive surgery. The system uses paired magnets to create incisionless, sutureless, staple-free side-to-side duodeno-ileal anastomoses that heal via natural tissue compression over 7-21 days, leaving no permanent implants. The MagDI™ System is sold as a set of sterile disposable magnets (40mm, 50mm), a Delivery System, a reusable Laparoscopic Positioning Device, and a Magnetic Retrieval Device to bariatric/metabolic surgeons at hospitals and ASCs.

Product overview

GT Metabolic Solutions offers the MagDI™ System as its core product platform—a proprietary magnetic compression anastomosis technology for bariatric and metabolic surgery. The system comprises the MagDI™ Magnets (40mm and 50mm variants), a Delivery System for orogastric magnet placement, a Laparoscopic Positioning Device (LPD) for intraoperative magnet positioning, and a Magnetic Retrieval Device (MRD) for emergency magnet retrieval. The technology enables incisionless, sutureless, staple-free creation of duodeno-ileal anastomoses by leveraging the body's natural healing process through magnetic compression.

Differentiator

Problem solved

Functional benefit

Products and services

• MagDI™ System The MagDI™ System is a proprietary magnetic compression anastomosis technology platform for creating incisionless, sutureless, staple-free side-to-side duodeno-ileal anastomoses in bariatric and metabolic surgery. It is sold to bariatric and metabolic surgeons at hospitals and Ambulatory Surgery Centers and consists of paired magnets, a delivery system, a laparoscopic positioning device, and a magnetic retrieval device.
• MagDI™ Magnets (40mm and 50mm) Parylene-C coated neodymium magnets encased in titanium shells with PGLA bio-fragmentable flanges, available in 40mm and 50mm sizes. Used for magnetic compression anastomosis in laparoscopic and minimally invasive bariatric surgery.
• MagDI™ Delivery System A disposable flexible orogastric delivery catheter, 198cm in length, with a ring handle pull trigger for easy magnet deployment. Must be paired with a flexible endoscope with a working channel of at least 2.8mm. Used by bariatric/metabolic surgeons to deliver and position the MagDI™ magnet in the duodenum.
• MagDI™ Laparoscopic Positioning Device (LPD) A 41cm reusable laparoscopic positioning device compatible with a 12mm trocar, featuring a Parylene-C coated neodymium magnet in a titanium housing with a non-magnetic shaft and positioning handle. Offered in five magnetic strengths to accommodate varying patient bowel morphology; used by bariatric surgeons to position the ileal magnet during the procedure.
• MagDI™ Magnetic Retrieval Device (MRD)

Quantifiable outcome

• Clinically meaningful weight loss and T2D mitigation demonstrated in prospective single-center 15-patient study published in JACS (August 2025)
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Levita Magnetics: Develops magnetic surgical platforms for laparoscopic procedures, including FDA-cleared magnetic graspers that reduce incision size. Most direct comparable in the magnetic surgery category, applying magnetic technology to surgical workflows though focused on retraction/lifting rather than anastomosis.
• Spatz Medical: Develops the Spatz3 adjustable gastric balloon, an endoscopic bariatric device. Direct comparable in endoscopic bariatric/metabolic space with similar patient population, ASC delivery model, and minimally invasive positioning.
• Allurion Technologies: Public company (NYSE: ALUR) offering a swallowable, procedure-less gastric balloon for weight loss. Direct comparable in non-surgical/incisionless bariatric interventions targeting similar obese patient population with similar outpatient delivery model.
• GI Dynamics: Develops the EndoBarrier, an endoscopic duodenal-jejunal bypass liner for Type 2 diabetes and obesity treatment. Direct comparable in endoscopic metabolic intervention targeting the same T2D-in-obese-patient indication via non-surgical GI modification.
• EndoGastric Solutions: Develops incisionless, transoral endoscopic procedures for GERD and other upper GI conditions, with former CEO Thierry Thaure on leadership team. Direct comparable in incisionless GI/endoscopic bariatric space with similar enterprise sales motion to hospitals and ASCs.

Broad incumbents

• Medtronic: Global medical device leader offering bariatric surgical stapling systems (Endo GIA), advanced energy devices, and bariatric surgery programs. Broad incumbent in bariatric/MIS space with established hospital relationships, scale manufacturing, and reimbursement infrastructure that GT Metabolic must displace.
• Ethicon: Johnson & Johnson subsidiary and market leader in surgical stapling (ECHELON), energy devices, and bariatric surgical products. Broad incumbent dominating the stapled anastomosis standard of care that MagDI technology aims to replace.
• Intuitive Surgical: Maker of the da Vinci robotic surgical platform with deep entrenchment in MIS bariatric and general surgery. Broad incumbent setting the MIS technology standard that GT Metabolic's laparoscopic positioning device must integrate with during procedures.
• Teleflex: Acquired Standard Bariatrics in 2022 to enter the bariatric stapling market with the Titan SGS standardized gastric stapling device. Broad incumbent in bariatric surgical stapling with similar ASC/hospital sales motion and complementary product positioning.
• Applied Medical: Privately-held manufacturer of MIS surgical instruments, trocars, and stapling devices. Broad incumbent supplying hospitals and ASCs with the type of disposable laparoscopic instruments that complement GT Metabolic's MagDI delivery system.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gt-metabolic-solutions

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GT Metabolic Solutions